-transparent.png){kind=logo}
In order to improve the management of lung cancer at various stages, we analyzed results of treatment in 928 of 1024 patients who were registered at our Hospital Tumor Registry of 1952-1983 with a pathological diagnosis of TNM for carcinoma of the lung after pulmonary resection. The 5-year-survival rate was 43% in 928 patients excluded the cases who were lost follow-up or succumbed within post-operative 1 month. The 5-year-survival rate was 77% for the stage I, 54.7% for the stage II, 17% for the stage III and 4% for the stage IV. The 5-year-survival rate by therapeutic modality was as follows: 52% for the group with chemotherapy, 35% for the one without adjuvant therapies, 29% for the one with irradiation and 15% for the one with radiochemotherapy. Patients with adenocarcinoma who underwent curative surgery showed improvement of survival by postoperative chemotherapy. No increase in survival time was noticed in the irradiated group with N2.
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
July 2004,
Clinical lung cancer,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
January 2008,
Kyobu geka. The Japanese journal of thoracic surgery,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
December 2016,
Prescrire international,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
November 2007,
The Annals of thoracic surgery,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
February 2003,
Gan to kagaku ryoho. Cancer & chemotherapy,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
December 2019,
Translational lung cancer research,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
March 2023,
Respiratory investigation,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
May 2000,
Clinical lung cancer,
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
April 2010,
Lancet (London, England),
K Hashimoto, and
M Sagawa, and
M Sato, and
N Nagamoto, and
K Usuda, and
S Ohta, and
K Kanma, and
T Imai, and
Y Saito, and
H Suda
July 1989,
Chest,
